Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.53 USD | -3.95% | -3.61% | -20.85% |
20/05 | Insmed Lung Infections Treatment Study Shows Improvement | MT |
15/05 | Goldman Sachs Adjusts Price Target on Insmed to $49 From $40, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.85% | 379.54Cr | |
+8.63% | 12TCr | |
+13.17% | 11TCr | |
-12.76% | 2.23TCr | |
-3.99% | 2.16TCr | |
-7.19% | 1.82TCr | |
-39.93% | 1.76TCr | |
+6.67% | 1.43TCr | |
+33.90% | 1.24TCr | |
-28.60% | 828.11Cr |
- Stock Market
- Equities
- INSM Stock
- News Insmed Incorporated
- Barclays Adjusts Insmed Price Target to $35 From $37, Maintains Overweight Rating